基础医学与临床 ›› 2017, Vol. 37 ›› Issue (3): 415-418.

• 短篇综述 • 上一篇    下一篇

suPAR在消化道肿瘤中的研究进展

张金铎1,林延延2,赵盛1,把永江1,孟文勃2,李汛2   

  1. 1. 兰州大学第一临床医学院
    2. 兰州大学第一医院
  • 收稿日期:2016-03-28 修回日期:2016-05-31 出版日期:2017-03-05 发布日期:2017-02-23
  • 通讯作者: 孟文勃 E-mail:mengwb@163.com
  • 基金资助:
    原发性肝癌侵袭、复发预警分子筛选;“西部之光”人才培养引进计划

Controversy of soluble urokinase-type plasminogen activator receptor in gastrointestinal cancer

  • Received:2016-03-28 Revised:2016-05-31 Online:2017-03-05 Published:2017-02-23

摘要: 可溶性尿激酶型纤溶酶原激活物受体(suPAR)是尿激酶型纤溶酶原激活物受体(uPAR)的可溶形式,其除作为一种炎性反应标志物外,在消化道肿瘤的发生发展及侵袭转移中也具有重要的生物学作用。研究表明,suPAR在早期肿瘤的分子诊断、治疗效果的监测及进一步生物靶向药物的开发中具有重要的价值。

关键词: 可溶性纤溶酶原激活物受体, 恶性肿瘤, 预后, 标志物

Abstract: Soluble urokinase- type plasminogen activator receptor (suPAR) is the soluble form of urokinase- type plasminogen activator receptor (uPAR). Besides being a new biomarker of inflammation, suPAR plays an important role in the growth, development, invasion and metastasis of gastrointestinal cancer. Recent research suggests that suPAR has significant value in the molecular diagnosis of incipient tumors, monitoring of the therapeutic response and further development of the molecular targeted new agents.

Key words: suPAR, cancer, prognosis, biomarker